

ThaÃs Baert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1056415/publications.pdf>

Version: 2024-02-01

22
papers

679
citations

840776

11
h-index

794594

19
g-index

22
all docs

22
docs citations

22
times ranked

1413
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 588.	4.8	317
2	Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1273.	4.8	65
3	Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients. <i>Gynecologic Oncology</i> , 2018, 150, 31-37.	1.4	42
4	Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course. <i>Oncolmmunology</i> , 2016, 5, e1111505.	4.6	31
5	Peripherally-driven myeloid NFkB and IFN/ISG responses predict malignancy risk, survival, and immunotherapy regime in ovarian cancer. , 2021, 9, e003609.		24
6	Opposite Macrophage Polarization in Different Subsets of Ovarian Cancer: Observation from a Pilot Study. <i>Cells</i> , 2020, 9, 305.	4.1	22
7	The dark side of ID8-Luc2: pitfalls for luciferase tagged murine models for ovarian cancer. , 2015, 3, 57.		17
8	Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1381-1388.	2.5	17
9	Ovarian cancer and the immune system. <i>Gynecologic Oncology Reports</i> , 2017, 19, 57-58.	0.6	16
10	Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. <i>Gynecologic Oncology</i> , 2020, 159, 434-441.	1.4	16
11	Circulating Protein Biomarkers to Differentiate Uterine Sarcomas from Leiomyomas. <i>Anticancer Research</i> , 2019, 39, 3981-3989.	1.1	14
12	The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer. <i>Anticancer Research</i> , 2016, 36, 5781-5792.	1.1	14
13	Increased Immunosuppression Is Related to Increased Amounts of Ascites and Inferior Prognosis in Ovarian Cancer. <i>Anticancer Research</i> , 2019, 39, 5953-5962.	1.1	13
14	CT-2A neurospheres-derived high-grade glioma in mice: a new model to address tumor stem cells and immunosuppression. <i>Biology Open</i> , 2019, 8, .	1.2	12
15	Type of chemotherapy has substantial effects on the immune system in ovarian cancer. <i>Translational Oncology</i> , 2021, 14, 101076.	3.7	11
16	In Vitro Generation of Murine Dendritic Cells for Cancer Immunotherapy: An Optimized Protocol. <i>Anticancer Research</i> , 2016, 36, 5793-5802.	1.1	11
17	Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer. <i>Cancers</i> , 2021, 13, 5899.	3.7	9
18	TRP channel expression correlates with the epithelial to mesenchymal transition and high-risk endometrial carcinoma. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 1.	5.4	9

#	ARTICLE	IF	CITATIONS
19	Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors. <i>Gynecologic Oncology</i> , 2020, 159, 811-819.	1.4	8
20	Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation “real life data. <i>Gynecologic Oncology</i> , 2021, 163, 569-577.	1.4	7
21	Circulating Transcripts and Biomarkers in Uterine Tumors: Is There a Predictive Role?. <i>Current Oncology Reports</i> , 2020, 22, 12.	4.0	4
22	Orientation of Preclinical Research in Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1579-1586.	2.5	0